This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2003 Jan 2;348(1):68-72.

doi: 10.1056/NEJMe020157.

Alpha4 integrins as therapeutic targets in autoimmune disease

Ulrich H von Andrian, Britta Engelhardt

PMID: 12510047
DOI: 10.1056/NEJMe020157

Editorial

Alpha4 integrins as therapeutic targets in autoimmune disease

Ulrich H von Andrian et al. N Engl J Med. 2003.

. 2003 Jan 2;348(1):68-72.

doi: 10.1056/NEJMe020157.

Authors

Ulrich H von Andrian, Britta Engelhardt

PMID: 12510047
DOI: 10.1056/NEJMe020157

No abstract available

PubMed Disclaimer

Comment on

A controlled trial of natalizumab for relapsing multiple sclerosis.
Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O'Connor PW; International Natalizumab Multiple Sclerosis Trial Group. Miller DH, et al. N Engl J Med. 2003 Jan 2;348(1):15-23. doi: 10.1056/NEJMoa020696. N Engl J Med. 2003. PMID: 12510038 Clinical Trial.
Natalizumab for active Crohn's disease.
Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnálek P, Zádorová Z, Palmer T, Donoghue S; Natalizumab Pan-European Study Group. Ghosh S, et al. N Engl J Med. 2003 Jan 2;348(1):24-32. doi: 10.1056/NEJMoa020732. N Engl J Med. 2003. PMID: 12510039 Clinical Trial.

Similar articles

Natalizumab for relapsing multiple sclerosis.
Tenser RB. Tenser RB. N Engl J Med. 2006 Jun 1;354(22):2387-9; author reply 2387-9. doi: 10.1056/NEJMc060894. N Engl J Med. 2006. PMID: 16738278 No abstract available.
Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?
Davenport RJ, Munday JR. Davenport RJ, et al. Drug Discov Today. 2007 Jul;12(13-14):569-76. doi: 10.1016/j.drudis.2007.05.001. Epub 2007 Jun 26. Drug Discov Today. 2007. PMID: 17631252 Review.
Iatrogenic immunosuppression with biologics in MS: expecting the unexpected?
Stüve O, Wiendl H. Stüve O, et al. Neurology. 2009 Oct 27;73(17):1346-7. doi: 10.1212/WNL.0b013e3181beed38. Epub 2009 Sep 23. Neurology. 2009. PMID: 19776376 No abstract available.
Asymptomatic reactivation of JC virus in patients treated with natalizumab.
Gorelik L, Goelz S, Sandrock AW. Gorelik L, et al. N Engl J Med. 2009 Dec 17;361(25):2487-8; author reply 2489-90. doi: 10.1056/NEJMc0909622. N Engl J Med. 2009. PMID: 20018972 No abstract available.
A balancing act--making the right choices in anti-inflammatory drug development.
Elices MJ. Elices MJ. Curr Opin Investig Drugs. 2007 May;8(5):362-3. Curr Opin Investig Drugs. 2007. PMID: 17520864 Review. No abstract available.

See all similar articles

Cited by

Cytokine Profile in Predicting the Effectiveness of Advanced Therapy for Ulcerative Colitis: A Narrative Review.
Kurumi H, Yokoyama Y, Hirano T, Akita K, Hayashi Y, Kazama T, Isomoto H, Nakase H. Kurumi H, et al. Biomedicines. 2024 Apr 25;12(5):952. doi: 10.3390/biomedicines12050952. Biomedicines. 2024. PMID: 38790914 Free PMC article. Review.
Long-lasting severe anemia following treatment with natalizumab for relapsing-remitting multiple sclerosis: a case report.
Hamnvik LHD, Tjønnfjord GE, Spetalen S, Dalgaard J. Hamnvik LHD, et al. J Med Case Rep. 2024 May 13;18(1):245. doi: 10.1186/s13256-024-04562-8. J Med Case Rep. 2024. PMID: 38736000 Free PMC article.
Vedolizumab for induction and maintenance of remission in Crohn's disease.
Hui S, Sinopoulou V, Gordon M, Aali G, Krishna A, Ding NS, Boyapati RK. Hui S, et al. Cochrane Database Syst Rev. 2023 Jul 17;7(7):CD013611. doi: 10.1002/14651858.CD013611.pub2. Cochrane Database Syst Rev. 2023. PMID: 37458279 Free PMC article. Review.
Study of tumor necrosis factor receptor in the inflammatory bowel disease.
Souza RF, Caetano MAF, Magalhães HIR, Castelucci P. Souza RF, et al. World J Gastroenterol. 2023 May 14;29(18):2733-2746. doi: 10.3748/wjg.v29.i18.2733. World J Gastroenterol. 2023. PMID: 37274062 Free PMC article. Review.
Phostensin enables lymphocyte integrin activation and population of peripheral lymphoid organs.
Lee HS, Sun H, Lagarrigue F, Kim SHJ, Fox JW, Sherman NE, Gingras AR, Ginsberg MH. Lee HS, et al. J Exp Med. 2022 Aug 1;219(8):e20211637. doi: 10.1084/jem.20211637. Epub 2022 Jun 29. J Exp Med. 2022. PMID: 35766979 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information